What are the unique pharmacovigilance considerations for biologics?

Biologics pharmacovigilance addresses unique safety considerations: 1) Immunogenicity monitoring - long-term ADA development, neutralizing antibodies, impact on PK and efficacy, cross-reactive antibodies to endogenous proteins (pure red cell aplasia with erythropoietin). 2) Batch traceability - track specific batches to patients; essential for investigating batch-related issues; unique identifier requirements. 3) Product-specific events - class effects may not apply across similar products; each product requires independent safety database. 4) Biosimilar extrapolation - safety data from one indication may support others, but monitoring required. 5) Signal detection - rare events require large exposed populations; post-marketing studies, registries. 6) Immunologically-mediated events - cytokine release syndrome (CAR-T), infusion reactions, immune-complex deposition. 7) Risk minimization - REMS programs, restricted distribution, healthcare provider certification. 8) Pregnancy registries - limited data, need for exposure registries. Collaboration between manufacturers, regulators, and healthcare systems essential.